Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) unveiled two clinical development programs to target antiviral and anti-seizure applications. Cure Pharmaceutical will add its known API (active pharmaceutical ingredient)...
Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) commenced the initial PK (Pharmacokinetics) trial that supports the previously approved IND application with the US FDA. The company initiated this...
Sera Labs has been at the helm of leadership in the consumer packaged goods industry. Over the years, it has also become a recognized frontrunner in...
Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) is pleased to announce the receipt of a Chinese Patent No. ZL201480039313.6. The new patent allows the company to load a...
Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) has agreed to collaborate with Canopy Growth Corp (NYSE:CGC) to develop innovative low dosage CBD Oral Thin Film (OTF). As per...
Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) has today disclosed details regarding the O’Cannabiz Conference & Expo that will be held in June. Rob Davidson, current CEO will...
Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) has mobilized $500,000 to expedite cannabinoid drug delivery production. The company has received a convertible loan from a strategic partner. Chief...
